Vivos: Non-Surgical Solution for Obstructive Sleep Apnea | VVOS
Clinical studies with Vivos devices have shown that 12.5–25% of patients may continue wearing a CPAP device. All content found on the vivos.com website—including text, images, audio, or other …
Vivos Therapeutics Receives First Ever FDA 510(k) Clearance for Oral ...
Nov 29, 2023 · The Vivos Method includes treatment regimens that employ the proprietary Vivos Complete Airway Repositioning and/or Expansion (CARE) appliance therapy and other modalities …
Vivos | Obstructive Sleep Apnea Patients
Based on your specific needs, your Vivos-trained dentist will conduct a comprehensive evaluation, taking all relevant clinical records, in order to formulate a customized treatment plan.
Vivos Therapeutics Receives FDA 510(k) Clearance of its Flagship DNA ...
Jan 4, 2023 · Vivos believes its patented appliances and related proprietary protocols offer significant advantages over existing OSA treatments. “This clearance is the culmination of years of pioneering …
Vivos Therapeutics’ Flagship CARE Oral Medical Devices Receive Full ...
Apr 8, 2024 · The three Vivos CARE devices open airway space and may significantly reduce symptoms and conditions associated with mild-to-severe OSA, such as lowering Apnea Hypopnea Index …
Find a Vivos Provider with our Locator - Vivos.com
View here and know where the nearest provider you can go and contact to! View many providers of Vivos now! Click here!
Vivos Therapeutics Completes Acquisition of The Sleep Center of Nevada
Jun 11, 2025 · Transaction brings OSA diagnostic revenue to Vivos, plus Vivos’ highly effective OSA treatment options to thousands of potential patients in the greater Las Vegas area
Vivos Therapeutics and SoundHealth Announce Collaboration to …
Feb 9, 2026 · The collaboration with Vivos will harness this dataset and SoundHealth’s innovative technology to explore educational and distribution initiatives across Vivos’ large provider network to …
Vivos Therapeutics Signs Definitive Agreement to Acquire Largest …
Apr 16, 2025 · Vivos has agreed to pay up to $9 million for the SCN operating assets, including $6 million in cash and $1.5 million in Vivos common stock at closing. An additional $1.5 million in Vivos …
Latest Clinical Study Show No Symptoms of Obstructive Sleep Apnea
Dec 15, 2022 · Vivos announced results from a national study commissioned by the Company to assess patients’ airway function and OSA symptoms.